Translational Potential of Allosteric Modulators Targeting the Cannabinoid CB Receptor

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2018 Oct 19

PMID 30333554

Citations 18

Authors

Dai Lu

Sri Sujana Immadi

Zhixing Wu

Debra A Kendall

Affiliations

Soon will be listed here.

Abstract

The cannabinoid type-1 (CB) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due to its involvement in many physiological processes. Historically, drug discovery efforts targeting the CB receptor have focused on the development of orthosteric ligands that interact with the active site to which endogenous cannabinoids bind. Research performed over the last several decades has revealed substantial difficulties in translating CB orthosteric ligands into druggable candidates. The difficulty is mainly due to the adverse effects associated with orthosteric CB ligands. Recent discoveries of allosteric CB modulators provide tremendous opportunities to develop CB ligands with novel mechanisms of action; these ligands may potentially improve the pharmacological effects and enhance drug safety in treating the disorders by regulating the functions of the CB receptor. In this paper, we review and summarize the complex pharmacological profiles of each class of CB allosteric modulators, the development of new classes of CB allosteric modulators and the results from in vivo assessments of their therapeutic value.

Citing Articles

Unraveling GPCRs Allosteric Modulation. Cannabinoid 1 Receptor as a Case Study.

Cruz A, Warshel A Proteins. 2024; 93(4):763-785.

PMID: 39584635 PMC: 11879764. DOI: 10.1002/prot.26762.

The State of Synthetic Cannabinoid Medications for the Treatment of Pain.

Maglaviceanu A, Peer M, Rockel J, Bonin R, Fitzcharles M, Ladha K CNS Drugs. 2024; 38(8):597-612.

PMID: 38951463 DOI: 10.1007/s40263-024-01098-9.

Negative allosteric modulation of CB cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception.

Iyer V, Saberi S, Pacheco R, Sizemore E, Stockman S, Kulkarni A Neuropharmacology. 2024; 257:110052.

PMID: 38936657 PMC: 11261750. DOI: 10.1016/j.neuropharm.2024.110052.

Chlorinated Enyne Fatty Acid Amides from a Marine Cyanobacterium: Discovery of Taveuniamides L-M and Pharmacological Characterization of Taveuniamide F as a GPCR Antagonist with CNR1 Selectivity.

Elsadek L, Ellis E, Seabra G, Paul V, Luesch H Mar Drugs. 2024; 22(1).

PMID: 38248654 PMC: 10817531. DOI: 10.3390/md22010028.

Zhu C, Lan X, Wei Z, Yu J, Zhang J Acta Pharm Sin B. 2024; 14(1):67-86.

PMID: 38239234 PMC: 10792987. DOI: 10.1016/j.apsb.2023.07.020.

References

Price M, Baillie G, Thomas A, Stevenson L, Easson M, Goodwin R . Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68(5):1484-95. DOI: 10.1124/mol.105.016162. View

Kenakin T, Miller L . Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010; 62(2):265-304. PMC: 2879912. DOI: 10.1124/pr.108.000992. View

Grover A . Use of allosteric targets in the discovery of safer drugs. Med Princ Pract. 2013; 22(5):418-26. PMC: 5586781. DOI: 10.1159/000350417. View

Varga E, Georgieva T, Tumati S, Alves I, Salamon Z, Tollin G . Functional selectivity in cannabinoid signaling. Curr Mol Pharmacol. 2009; 1(3):273-84. DOI: 10.2174/1874467210801030273. View

Morales P, Reggio P, Jagerovic N . An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front Pharmacol. 2017; 8:422. PMC: 5487438. DOI: 10.3389/fphar.2017.00422. View

Khurana L, Fu B, Duddupudi A, Liao Y, Immadi S, Kendall D . Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB. J Med Chem. 2017; 60(3):1089-1104. PMC: 5724760. DOI: 10.1021/acs.jmedchem.6b01448. View

Howlett A, Blume L, Dalton G . CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem. 2010; 17(14):1382-93. PMC: 3179980. DOI: 10.2174/092986710790980023. View

Mackie K . Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008; 20 Suppl 1:10-4. DOI: 10.1111/j.1365-2826.2008.01671.x. View

Lauckner J, Hille B, Mackie K . The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A. 2005; 102(52):19144-9. PMC: 1323208. DOI: 10.1073/pnas.0509588102. View

10.

Vaidehi N, Kenakin T . The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol. 2010; 10(6):775-81. DOI: 10.1016/j.coph.2010.09.004. View

11.

Atwood B, Straiker A, Mackie K . CB₂: therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 38(1):16-20. PMC: 3345167. DOI: 10.1016/j.pnpbp.2011.12.001. View

12.

Han S, Thatte J, Buzard D, Jones R . Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem. 2013; 56(21):8224-56. DOI: 10.1021/jm4005626. View

13.

Smith T, Blume L, Straiker A, Cox J, David B, McVoy J . Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation. Mol Pharmacol. 2015; 87(4):747-65. PMC: 4366794. DOI: 10.1124/mol.114.096495. View

14.

Yang P, Wang L, Xie X . Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med Chem. 2012; 4(2):187-204. PMC: 3501202. DOI: 10.4155/fmc.11.179. View

15.

Pisanti S, Malfitano A, Ciaglia E, Lamberti A, Ranieri R, Cuomo G . Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041. View

16.

Di Marzo V, Bifulco M, De Petrocellis L . The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004; 3(9):771-84. DOI: 10.1038/nrd1495. View

17.

Turner S, Williams C, Iversen L, Whalley B . Molecular Pharmacology of Phytocannabinoids. Prog Chem Org Nat Prod. 2017; 103:61-101. DOI: 10.1007/978-3-319-45541-9_3. View

18.

Gamage T, Anderson J, Abood M . CB allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling. Cannabis Cannabinoid Res. 2017; 1(1):272-280. PMC: 5484173. DOI: 10.1089/can.2016.0028. View

19.

Busquets-Garcia A, Soria-Gomez E, Redon B, Mackenbach Y, Vallee M, Chaouloff F . Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol Psychiatry. 2017; 22(11):1594-1603. PMC: 5447368. DOI: 10.1038/mp.2017.4. View

20.

Grotenhermen F, Muller-Vahl K . The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012; 109(29-30):495-501. PMC: 3442177. DOI: 10.3238/arztebl.2012.0495. View